Ceva-Phylaxia Expands Monor Presence with New Vaccine Production Unit
2024. 11. 14.
As part of its commitment to expanding its presence in Hungary, global animal vaccine producer Ceva-Phylaxia has announced an EUR 75 million investment, establishing a state-of-the-art unit in Monor dedicated to manufacturing inactivated, multicomponent vaccines. Following the official groundbreaking ceremony for the 7,000-square-meter facility, production is expected to begin by the end of 2026.
France-based Ceva Santé Animale, ranks as the fifth-largest animal health company globally. With a team of skilled veterinarians and experts, Ceva is committed to offering innovative and advanced health solutions that guarantee the highest quality of animal care and welfare. Their portfolio includes a wide range of vaccines, animal welfare products, and pharmaceutical solutions for both livestock and pets.
Ceva has a century-long history in Hungary through Phylaxia, making it a significant player and employer in the country’s animal health industry, with around 1,300 employees across its sites in Budapest and Monor. The company is now strengthening its presence in Hungary with its sixth manufacturing unit, dedicated to the production of animal health vaccines.
The newly established production facility will have the capacity to produce up to 8 billion doses of inactivated, multicomponent vaccines annually. This expansion will also create 120 new jobs in Monor, reinforcing Ceva’s long-term commitment to the Hungarian market.
